Market Access NHS to offer Wegovy to a million more people in England PharmaphorumThe NHS in England will make Novo Nordisk's Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes.Market AccessMetabolic & GLP-1Read full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaphorum The NHS in England will make Novo Nordisk’s Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes. Market AccessMetabolic & GLP-1Read full story Post navigation Previous: S16 Ep43: FDA Approval Insights: Rucaparib for BRCA Mutation-Associated mCRPC: With David Morris, MD, FACS; and Alan H. Bryce, MDNext: ACC 2026: Tonlamarsen lowers angiotensinogen without extra BP benefit Related Stories Market Access Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing pharminent September 2, 2026 Market Access How cost and perception could reshape the GLP-1 market pharminent August 21, 2026 Market Access D.C. Circuit Affirms HHS Authority Over 340B Rebate Models pharminent July 24, 2026